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Abstract
Background: Stimulation of CD137 ligand on human monocytes has been shown to induce DC differentiation, and these
CD137L-DCs are more potent than classical DCs, in stimulating T cell responses in vitro. To allow an in vivo evaluation of the
potency of CD137L-DCs in murine models we aimed at generating murine CD137L-DCs.
Methodology/Principal Findings: When stimulated through CD137 ligand murine monocytes responded just as human
monocytes with an increased adherence, morphological changes, proliferation and an increase in viable cell numbers. But
CD137 ligand signaling did not induce expression of inflammatory cytokines and costimulatory molecules in murine
monocytes and these cells had no T cell stimulatory activity. Murine monocytes did not differentiate to inflammatory DCs
upon CD137 ligand signaling. Furthermore, while CD137 ligand signaling induces maturation of human immature classical
DCs it failed to do so with murine immature classical DCs.
Conclusions/Significance: These data demonstrate that both human and murine monocytes become activated by CD137
ligand signaling but only human and not murine monocytes differentiate to inflammatory DCs.
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Introduction
Mice have long been invaluable in helping immunologists to
understand how immunity works, especially when systemic effects
of immune modulations were studied. Many immunotherapeutic
approaches, such as neutralization of inflammatory cytokines for
treatment of autoimmune disease have been pioneered in mice [1].
Despite many similarities, differences exist between the human
and murine immune system. For example peripheral monocytes in
man consist of two subpopulations of which the CD14
high, CD16
2
cells constitute to 90–95% and the CD14
dim, CD16
+ cells
constitute 5–10% [2]. CD14 and CD16 are not suitable to
distinguish murine monocyte subpopulations. Rather, in the
murine system monocyte subpopulations are classified as
CD115
+, Ly6C
high and CD115
+, Ly6C
low, respectively, which
constitute 50% each [3].
Both human and murine monocytes express CD137 ligand
(TNFSF9, 4-1BB ligand), a member of the TNF superfamily [4,5].
CD137 ligand not only sends signals to CD137-expressing cells but
it is a transmembrane protein on the cell surface that can also
deliver signals into the cells it is expressed on (reverse signaling),
[6]. Peripheral human monocytes are activated by CD137 ligand
signaling, evidenced by enhanced adherence, increased expression
of ICAM-1 and secretion of proinflammatory cytokines [7,8],
increased survival [9], induction of proliferation [10,11] and
enhanced migration [12,13]. Murine macrophages are similarly
activated by CD137 ligand signaling also leading to enhanced
adherence, increased expression of ICAM-1 and secretion
proinflammatory cytokines [14,15].
CD137 ligand signaling can also induce maturation of human
immature monocyte-derived DCs leading to an enhanced expres-
sion of costimulatory molecules, IL-12 secretion, and an enhanced
capacityoftheDCsto stimulate T cell proliferation,IFN-c secretion
and in vivo migration towards a CCL19 gradient [16–18].
Two recent studies report that CD137 ligand signaling induces
full human monocyte to DC differentiation. CD137 ligand
signaling triggered by a monoclonal anti-CD137 ligand antibody
and complemented by IL-4 induced costimulatory molecule
expression and T cell stimulatory activity [19]. However,
recombinant CD137 protein as a sole factor is sufficient to induce
human monocyte to DC differentiation and these CD137L-DCs
are more potent than classical DCs in inducing proliferation, IFN-
c secretion and perforin expression by T cells [20].
These data indicate that CD137L-DCs may also be more potent
ininducing protectiveT cellresponsesthan classicalDCs.However,
a reliable conclusion about the potency of the different DC
populations should be based on in vivo experiments. As these would
be most easily performed in mice we tested whether CD137 ligand
signaling also induces DC differentiation in murine monocytes, so
that murine CD137L-DCs can be tested for their ability to induce
anti-pathogen and anti-tumor immune responses in vivo.
Just as in human monocytes CD137 ligand signaling induced
attachment, morphological changes and proliferation in murine
monocytes. However, neither monocyte to DC differentiation nor
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pointing to a species difference in the effects of CD137 ligand
signaling between human and murine monocytes.
Materials and Methods
Mice
Female Balb/C mice between 6 and 8 weeks of age were used as
a source of bone marrow cells. Animals were specific pathogen
free, and kept with free access to food and water in the animal care
facility at the National University of Singapore under the
institutional guidelines for usage of experimental animals (protocol
number 018-10).
Isolation of CD11b
+, Ly6G
2 monocytes from bone
marrow
The femur bones of Balb/C mice were dissected and the bone
marrow was flushed out aseptically with phosphate-buffered saline
(PBS), 2 mM EDTA by using a 10 ml syringe and 27G needle.
Total bone marrow cells were passed through 30((m filter (Miltenyi
Biotec, Bergisch Gladbach, Germany), washed with PBS, 2 mM
EDTA and resuspended in RPMI1640 (Sigma, St. Louis, MO,
USA), 10% fetal bovine serum (FBS).
The CD11b
+, Ly6G
2 monocytes were isolated by negative
selection using the mouse monocyte enrichment kit (Stemcell
Technologies, Vancouver, CA) following the manufacturer’s
instructions. Briefly, fresh bone marrow cells were labeled with a
cocktail of biotinylated antibodies against a panel of antigens
expressed on T, B, NK, DCs, progenitor cells and granulocytes,
followed by anti-biotin microbeads. The cell suspension was
incubated within a 5 ml polystyrene tube that fits in the Easysep@
magnet device. Unlabled monocytes were obtained by inverting
the tube in the magnet and dispensing the cell solution into a new
tube.
Recombinant proteins and chemicals
Recombinant human CD137-Fc protein was purified from
supernatants of stable transfected CHO cells by protein G
sepharose, as described previously [21]. The endotoxin concen-
tration in the CD137-Fc protein is 55 I.U./mg. Human IgG1 Fc
protein was purchased from Accurate Chemical and Scientific
Corporation (Westbury, NY, USA). Recombinant mouse CD137-
Fc protein was purchased from R&D systems (Minneapolis, MN,
USA). Recombinant murine TNFRI-Fc and CD134-Fc protein
were obtained from R&D Systems. Recombinant murine GM-
CSF and IL-4 were purchased from PeproTech (Rocky Hill, NJ,
USA). LPS was obtained from Sigma.
Antibodies and flow cytometry
Phycoerythrin (PE)-conjugated and Flourescein isothiocyanate
(FITC) labeled rat anti-mouse mouse CD11c, CD14, CD80,
CD86, F4/80, major histocompatibility complex (MHC) class II,
and respective isotype controls (rat IgG2a, rat IgG2b, Armenian
Hamster IgG) were purchased from eBioscience (San Diego,
USA).
Flow cytometry was performed on a Cyan flow cytometer
(Dako, Denmark) with Summit software. Nonspecific staining was
controlled by isotype-matched antibodies.
Cell count by flow cytometry
For the flow cytometry based cell count, cells were harvested
after incubation with 10 mM EDTA for 10 min. Cells were
centrifuged and resuspended in PBS and stained with 0.5((g/ml 7-
AAD for 15 min at RT in dark. After washing three times the cells
were resuspended in 450((l PBS. 50((l of Sphero Accucount Blank
Particles (1000 beads per (l) were added to the suspension and
mixed. Samples were analyzed by flow cytometry with CyanTM
(Beckman Coutler, CA, USA). 7-AAD-negative cells were gated as
live cells. Beads and target cells were gated separately on the
forward/side scatter plot based on the different sizes. The number
of cells in each sample was calculated by the following formula:
Number of cells in sample = (50,000 x Number of counted cells)/
Number of counted beads.
Proliferation assay
Cell proliferation was determined by
3H-thymidine incorpora-
tion. Cells were pulsed with 0.5 mCi of
3H-thymidine (PerkinEl-
mer, Boston, MA) for the last 24 h of the culture period. The cells
were then harvested onto a Packard Unifilter Plate using a
MicroMate 196 Cell Harvester and counted using a TopCount
Microplate Scintillation Counter (Packard Instruments, Meriden,
CT).
Phagocytosis Assay
Yellow-green flourescent carboxylated-modified microspheres
(FluroSpheres, Molecular Probes) were added at a ratio of 50
beads per cell at 37uC in the dark. Cells undergoing the same
treatment but without the additions of beads served as negative
controls. After 1 h incubation, the reaction was arrested by
addition of 1 ml ice-cold PBS. Cells were then washed in PBS and
trypsin-EDTA was added to dislodge surface adherent beads. Cells
were washed again and resuspended in FACS buffer for flow
cytometry analysis.
Allogeneic mixed lymphocyte reaction
2610
5 CD11b
+, Ly6G
2 monocytes per well were cultured in
24-well plates that had been precoated with 10 mg/ml of Fc or
CD137-Fc. In parallel, cells were treated with 100 ng/ml GM-
CSF +25 ng/ml IL-4 (Peprotech) to generate immature classical
DCs. Maturation of DCs and CD137-treated monocytes was
induced on day 6 by addition of 1 mg/ml LPS (Sigma).
Subsequently, cells were harvested by incubation with 10 mM
EDTA at RT for 10 min and washed twice with PBS, and served
as stimulator cells. T cells were isolated from splenocytes of 6-week
old C57/BL6 mice by magnetic selection using the Pan T cell
isolation kit (Miltenyi Biotec). 10
5 T cells were cocultured with
stimulator cells at a 10:1 ratio in 96-well round bottom plates, and
proliferation was determined on day 3 by
3H-thymidine
incorporation.
ELISA
The concentrations of IL-10, IL-12p70 and soluble CD137 in
cell supernatants were determined by mouse IL-10, IL-12 (p70),
murine soluble CD137 DuoSet (R&D) and MCP-1 (Peprotech)
according to the manufacturers’ instructions. All measurements
were done in triplicate.
Microscopy
Morphological changes of cells were documented by using a
Zeiss Axiovert 40 inverted microscope (Zeiss, Go ¨ttingen, Ger-
many) and Canon PowerShot G6 digital camera.
Statistics
Statistical significance was determined by the two-tailed
unpaired Student’s t-test.
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CD137 ligand signaling induces activation of murine
monocytes
As a source for murine monocytes CD11b
+, Ly6G
2 bone
marrow cells were employed. CD137 ligand signaling was initiated
as previously described for human peripheral monocytes. Cells
were grown on plates that had been coated with a fusion protein
consisting of the extracellular domain of human or murine CD137
fused to the constant domain of human IgG1 (Fc). Wells coated
with an equal concentration of the Fc protein were used as
negative controls.
In response to CD137 ligand signaling the cells attached to the
plates, spread and formed lamellipodia (Figure 1A), similar to what
has been shown for human monocytes [7]. In contrast, classical
DCs induced by GM-CSF + IL-4 showed formed clusters and a
substantial proportion of the cells remained in suspension. Of the
Fc-treated control monocytes only few cells attached to the plate,
and majority of the attached cells lacked lamellipodia formation.
After a 7 day culture period five-times more live cells were
present in the CD137-Fc-coated wells compared to Fc-coated
wells (Figure 1B). The increased number of live cells resulting from
treatment with CD137-Fc protein could be the result of prolonged
cell survival and/or induction of proliferation. Indeed, CD137
ligand signaling induced a significant proliferation of monocytes
while control cultures did not proliferate (Figure 1C). These data
demonstrate that in murine and human monocytes CD137 ligand
signaling induces adherence, morphological changes and prolifer-
ation in a comparable way.
Absence of proinflammatory activation markers
In human monocytes CD137 ligand signaling induces strong
expression of costimulatory molecules which is further enhanced
by DC maturation signals such as LPS and IFN-c [18–20].
However, in murine monocytes CD137 ligand signaling only
marginally induced expression of CD80 and CD86 and the
addition of LPS had little or no effect, while high levels were
expressed on classical DCs (Figure 2A). The reverse was the case
for F4/80, a murine macrophage marker which was low on
classical DCs and high on CD137-treated monocytes (Figure 2A).
CD14 was expressed by both classical DCs and CD137-Fc-treated
monocytes but not by Fc-treated control monocytes (Figure 2A).
Figure 1. Activation of murine monocytes by recombinant CD137 protein. Monocytes were cultured under indicated conditions for 7 days.
(A) Morphological changes were documented by photography at 20x (upper panel) and 63x (lower panel) magnifications. (B) Numbers of viable cells
were determined by flow cytometry using Sphero Accucount Blank Particles. (C) Proliferation was determined by
3H-thymidine incorporation at 3 day
of culture. *: p,0.05. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016129.g001
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enhanced on CD137-treated monocytes (about 10-fold, from 3.1 to
29.3%) but few of these CD11c
+cells expressed also MHC class II and
only low levels. As in the case of costimulatory molecule expression the
addition of LPS had no effect. In contrast, among classical DCs the
CD11c
+,M H Cc l a s sI I
+ fraction was the largest subpopulation (46%),
and expressed high levels of MHC class II (Figure 2B).
IL-12 is secreted by mature DCs and is involved in mediating T
cell stimulation, while IL-10 is a potent inhibitor of DC activities.
As expected classical mature DCs secreted IL-12 but not IL-10
(Figure 2C). The pattern was the opposite for CD137-Fc-treated
monocytes which produced IL-10 but not IL-12. The Fc-treated
control cells also produced IL-10 and no IL-12. While stimulation
by LPS had little effect on expression of CD80, CD86, MHC class
II and IL-12, it synergized with CD137 ligand signaling in
inducing IL-10 secretion (Figure 2C).
Soluble forms of CD137 (sCD137) are generated by differential
splicing and may limit DC activation [22,23]. Murine splenic DCs and
bone marrow-derived DCs have been reported to secrete sCD137, and
maturation by LPS enhances sCD137 secretion [24]. We could
confirm high sCD137 secretion by classical mature bone marrow-
derived DCs but found that CD137-Fc-treated murine monocytes did
not secrete sCD137 (Figure 2C). This is in line with the missing IL-12
secretion, expression of costimulatory molecules and the T cell
stimulatory activity of CD137-Fc-treated murine monocytes.
Phagocytosis is reduced during differentiation of human
monocytes to classical DCs and CD137L-DCs [20,25]. In
contrast, CD137 ligand signaling increased phagocytosis of murine
monocytes (Figure 2D). This difference became even more
pronounced when beads attached unspecifically to the cell surface
were removed by trypsinization of the cells (Figure 2D).
The failure of CD137 ligand signaling to induce expression of
costimulatory molecules and proinflammatory cytokines in
murine monocytes contrasts its activities in human monocytes.
Also, in human monocytes CD137 ligand signaling reduced IL-
10 levels and the phagocytotic capacity while in murine
monocytes it had the opposite effect. These data indicate (1)
that there is a species difference in the response of human and
murine monocytes to CD137 ligand signaling, and (2) that
murine monocytes stimulated by CD137 protein may not
become inflammatory DCs.
CD137 ligand signaling fails to induce DC differentiation
and maturation
Classical DCs derived from Balb/C mice induced a strong
proliferation of T cells in a mixed lymphocyte reaction (MLR).
CD137-Fc-treated monocytes were devoid of this activity and also
the addition of LPS during the last 24 h could not confer a T cell
stimulatory activity. Fc-treated control monocytes also did not
induce T cell proliferation (Figure 3A).
Figure 2. Absence of DC characteristics. Monocytes were cultured under indicated conditions for 7 days. (A) Expression of CD80, CD86, F4/80
and CD14 were determined by flow cytometry. Numbers in the graphs represent the percentages of positively stained cells (grey histograms)
compared to the isotype control (open histograms). (B) Expression of CD11c and MHC-II were determined by flow cytometry. Numbers in the graphs
represent percentage of the population in each quadrant. (C) Cytokine secretion. The concentrations of (A) IL-10, (B) IL-12, and (C) soluble CD137 in
the supernatants were measured by ELISA. *p,0.05. N.D: Not detectable. (D) Phagocytosis was determined by adding flourescent beads to cells at a
ratio of 50:1. The flourescence was determined by flow cytometry. Numbers in the graphs indicate the percentages of positive cells and mean
fluorescence intensities (MFI). Half of the harvested cells were trypsinized to remove non-phagozytosed beads that might have stuck on the surface
of the cells. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016129.g002
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CD34
+ hematopoietic progenitor cells or peripheral blood by
cytokine stimulation could be matured by CD137 ligand agonists
to inflammatory DCs [16–18]. After having found that in murine
monocytes CD137 ligand signaling does not induce differentiation
to inflammatory DCs we wondered whether it would at least
induce maturation of immature classical DCs.
Total bone marrow cells were differentiated to immature DCs
by a 7 day culture with GM-CSF + IL-4 and were then matured
with either LPS or CD137 protein. Maturation by LPS strongly
increased expression of CD40 (8.9 vs 33.7% positive cells) and
CD86 (21.0 vs 60.1% positive cells) whereas the Fc control protein
or CD137-Fc had no effect. Expression of CD80 was not changed
by any of the three treatments (Figure 3B). These data indicate
that CD137 ligand signaling not only fails to induce DC
differentiation in murine monocytes but also maturation of
immature DCs.
The role of cell attachment in monocyte activation
In order to determine whether CD137-induced activation of
monocytes was a consequence of recombinant CD137-Fc protein
binding to CD137 ligand and thereby inducing monocyte
attachment we compared the effects of CD137-Fc protein to the
effects of two related proteins. Like CD137, TNF receptor I
(TNFRI) and CD134 (OX40) are members of the TNFR family,
and TNFRI-Fc and CD134-Fc protein are constructed in a similar
manner and resemble in structure the CD137-Fc protein.
TNFRI-Fc induced attachment and morphological changes in
murine monocytes that were similar to the ones induced by
CD137-Fc, while CD134-Fc was inactive (Figure 4A). The
numbers of live cells were elevated in all three treatment groups
with CD137-Fc having the most potent effect (Figure B). TNFRI-
Fc induced the highest secretion of IL-10 and MCP-1. CD134-Fc
only induced low levels of MCP-1 and no IL-10 (Figure 4C).
These data demonstrate the qualitatively different effects of the
three recombinant receptor fusionproteinsonmonocyte attachment,
viability and activity, and indicate that the activities of recombinant
CD137-Fc protein are due to CD137 ligand signaling, and are not
merely a consequence of CD137-induced monocyte attachment.
Analysis of alternative myeloid cell populations and
CD137 ligand agonists
The above data point to a clear species difference between
human and murine monocytes in regards to the effects of CD137
ligand signaling. However, a concern was that the observed
differences may be due to the different cell populations. Since it is
not feasible to isolate large numbers of peripheral murine
monocytes CD11b
+, Ly6G
2 bone marrow cells were used instead
since they are regarded as the murine equivalent of human
peripheral monocytes. To further confirm the obtained results and
to ensure that the obtained data are representative of murine
monocytic cells and not just to CD11b
+, Ly6G
2 bone marrow
cells we treated total bone marrow cells, CD11b
+ bone marrow
cells and CD11b
+ spleen cells with CD137-Fc protein. An
allogenic MLR showed that upon treatment with CD137-Fc
protein neither bone marrow nor splenic CD11b
+ cells differen-
tiated to stimulatory DCs (Figure 5A).
For all of the above experiments we had used human CD137-Fc
protein. Though human CD137 protein had been shown to
activate murine leukocytes [12,26] we stimulated CD11b
+, Ly6G
2
monocytes with human and murine CD137-Fc protein. There was
no difference in the phenotype of the cells as neither protein was
able to induce differentiation to stimulatory DCs as reflected by
their inability to secrete IL-12 (not shown) and by their inability to
induce T cell proliferation in an allogeneic MLR (Figure 5B). Also,
the expression of the macrophage markers CD14 and F4/80 was
highly comparable on monocytes that were treated with human or
murine CD137-Fc protein (Figure 5C). This rules out that the
Figure 3. CD137-treated monocytes exert no DC activity. (A) Monocytes from Balb/C mice were cultured for 7 days on plates with
immobilized Fc or CD137-Fc protein and where indicated stimulated by LPS for the last 24 h. The cells were cocultured with T cells from C57/Bl6 mice
in an allogeneic MLR at a ratio of 1:10. The rate of proliferation was determined by
3H-thymidine incorporation three days later. iDC: immature DC:
monocytes treated for 7 days with GM-CSF + IL-4. DC: iDC stimulated with LPS for 24 h. (B) Maturation of classical iDCs. Immature DCs were treated as
indicated for 3 days. Expression of costimulatory molecules (grey histograms) was determined by flow cytometry. Isotype control (open histograms).
Numbers in the graphs indicate the percentages of positive cells. *p,0.05. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016129.g003
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CD137 stimulation was due to a mismatched protein.
Discussion
It was recently reported that CD137 ligand signaling induces
differentiation of peripheral human monocytes to inflammatory
DCs, and that these CD137L-DCs are more potent than classical
DCs that were generated by GM-CSF + IL-4 and matured by LPS
+ IFN-c. DCs hold great potential for immunotherapy but
currently patient response rate is still low, and induced immune
responses are often too weak [27,28]. More potent DCs would be
expected to enhance the efficacy of immunotherapy. The
generation of the murine equivalent of the human CD137L-DCs
promised to allow extending the characterization of CD137L-DCs
from in vitro experiments to murine models and thereby obtaining
more relevant in vivo data on the potency of CD137L-DCs.
Based on the reports with human CD137L-DCs we expected
CD137 ligand signaling to induce differentiation of murine
monocytes to inflammatory DCs. Indeed, the phenotypical
response, i.e. increased attachment, morphological changes and
induction of proliferation were identical between monocytes from
the two species. But surprisingly, CD137 treatment failed to
generate inflammatory DCs from murine monocytes.
Addition of LPS as a maturation factor did not convert the
monocytes to inflammatory DCs but rather enhanced their IL-10
secretion while inducing no IL-12. Therefore, it has to be concluded
that a species difference exists between murine and human
monocytes in their differentiation response to CD137 ligand
signaling. While human monocytes differentiate to inflammatory
DCs murine monocytes do not. It is at present entirely unknown
what the biological reason for this species difference may be.
This species difference becomes also evident in the effects of
CD137 ligand signaling on immature classical DCs that were
Figure 4. Comparison of CD137-Fc, TNFRI-Fc and CD134-Fc. Monocytes were cultured under indicated conditions for 7 days. (A)
Morphological changes were documented by photography at 20x magnification. (B) Numbers of viable cells were determined by flow cytometry
using Sphero Accucount Blank Particles. (C) The concentrations of IL-10 and MCP-1 in the supernatants were measured by ELISA. N.D: Not detectable.
*p,0.05. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016129.g004
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classical DCs to CD137 protein or CD137-expressing cells induces
maturation as evidenced by higher expression of costimulatory
molecules and IL-12, stronger migratory activity and a higher T
cell stimulatory capacity [16–18]. In contrast, CD137 ligand
signaling did not induce costimulatory molecule and IL-12
expression in murine immature, classical DCs.
This species difference may have its molecular basis in the low
conservation of human and murine CD137 ligand. While the
amino acid sequence identity between other human and murine
members of the TNF family range between 70 and 80%, it is only
36% for CD137 ligand [29]. Therefore, it seems plausible that
different signaling pathways and accordingly different biological
effects are initiated by human and murine CD137 ligand signaling.
Nevertheless, this species difference was unexpected since CD137
ligand signaling has the same effect on human and murine
hematopoietic progenitor cells and induces macrophage differen-
tiation in both species [26,30]. However, species differences
between man and mouse have already been described for the
CD137 receptor/ligand system. While CD137 signaling delivers
potent costimulatory signals to both human and murine T cells it
affects NK cells differently in the two species. Crosslinking of
CD137 enhances the activity of murine NK cells [31] while it
inhibits cytotoxicity and IFN-c release of human NK cells [32].
Due to the species difference of CD137 ligand signaling on
human and murine monocytes future in vivo studies to
characterize CD137L-DCs cannot be conducted in mice. The
further characterization of CD137L-DCs has to rely on in vitro
experiments with human cells or on mice with a reconstituted
human immune system or possibly on primates.
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